Charles River Labs International Inc. investors’ quest to revive their proposed class action alleging misleading statements about the company’s sourcing of non-human research primates appeared to get a sympathetic ear at the First Circuit Monday.
The judges at the appellate panel quizzed Charles Labs’ attorney on his characterization of CEO and company statements about the drug developer’s connection to indicted suppliers and about the effect of the indictments on its business. At least two members of the US Court of Appeals for the First Circuit panel expressed doubt about the company’s argument.
The case stems from Charles River’s use ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.